|
13.11.2015 22:15:12
|
Minerva Neurosciences to Present at Jefferies 2015 London Healthcare Conference on November 18, 2015
| WALTHAM, Mass., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2015 London Healthcare Conference on November 18, 2015 at 9:00 a.m. Eastern Time. The presentation will be web cast and accessible through the investor relations section of the Company's web site, http://ir.minervaneurosciences.com. About Minerva Neurosciences: Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), in Phase IIa and Phase Ib development for insomnia and adjunctive major depressive disorder (MDD), respectively; MIN-117, in Phase IIa development for MDD; and MIN-301, in pre-clinical development for the treatment of Parkinson's disease. Minerva's common stock is listed on the Nasdaq Global Market under the symbol "NERV." For more information, please visit www.minervaneurosciences.com. CONTACT: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376 |
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
HUG#1966794
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Minerva Neurosciences Incmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Minerva Neurosciences Incmehr Analysen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.